Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Exploratory Clinical Study of FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR/MSS Colorectal Cancer

NCT07446465 is registered in ClinicalTrials.gov with Ye Xu as lead sponsor.

NCT NCT07446465
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07446465 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Exploratory Clinical Study of FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR/MSS Colorectal Cancer
Lead sponsor
Ye Xu
Phase
Phase 4
Overall status
Not yet recruiting
Start date
March 1, 2026
Completion date
January 31, 2027
Enrollment
42 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer (locally advanced or metastatic), colorectal cancer microsatellite stable (mss)